<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Q219 US Hemostats & Sealants Market Recap: Slightly Lower Growth YoY

Posted by Doug Devens on 9/6/19 11:31 AM

The US market for Hemostats and Sealants grew +6.4% YoY in Q219, a slightly lower growth rate vs Q119, with biologic sealants and thrombin hemostats driving the increase.

As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the US Hemostats and Sealants market, except Ethicon, experienced revenue growth in Q219. Leading the way was Baxter, as it capitalized on Ethicon’s supply problems with SurgifloCryolife and Becton Dickinson (BD) both posted strong gains. Ethicon still continued to dominate the overall US Hemostat and Sealants market, with a 40.7% share, down from 48.6% share in Q119. Most of this share shifted to Baxter as the Company continues to chip away at...

Among the many topics covered in the Q219 US Hemostats and Sealants Market Recap* are:

Read More

Topics: Biosurgery-Hemostats and Sealants

Q418/FY18 Market Recap: US Hemostats and Sealants

Posted by Doug Devens on 4/9/19 1:39 PM

The US market for Hemostats and Sealants accelerated in Q418 driven by growth in fibrin sealants and thrombin hemostats, overcoming slow growth during the first half of the year.

The US market for Hemostats and Sealants accelerated with +9.3% YoY growth in Q418, continuing to build on its +7.9% YoY in Q318, with fibrin sealants and thrombin hemostats driving the increase. The US market grew +6.1% in FY18, overcoming slow growth during the first half of the year.

As reported in SmartTRAK Financial Dashboard, every manufacturer in the Hemostats and Sealants market, except Pfizer and CryoLife, experienced revenue growth in Q418. Leading the way was Baxter with +33.1% YoY growth as it made progress with its integration of the Mallinckrodt portfolio. Ethicon and Becton Dickinson (BD) both posted solid gains, with +8.7% YoY and +6.6% YoY growth, respectively...

Read More

Topics: Biosurgery-Hemostats and Sealants, Q418 Market Recaps

Q318 US Hemostats and Sealants Market Recap

Posted by Doug Devens on 1/3/19 12:00 PM

The US market for Hemostats and Sealants accelerated substantially in Q318 vs Q218

As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the Hemostats and Sealants market, with the exception of Pfizer, saw revenue growth in Q318. Leading the way were Baxter, with its integration of the Mallinckrodt portfolio, as well as Ethicon and Integra, while Pfizer posted...

Among the many topics covered in the Q318 US Hemostats and Sealants Market Recap are:

Read More

Topics: Biosurgery-Hemostats and Sealants, Q318 Market Recaps

Top Trends in the Hemostats and Sealants Market

Posted by Doug Devens on 11/5/18 9:00 AM

The Hemostats and Sealants Market continues to grow at a steady clip. SmartTRAK projects this market will reach more than $3.5B by 2022E with a five-year CAGR of ~5%.

It’s good news for many, but do you know the real story behind those numbers?

SmartTRAK identifies what’s driving growth in the global Hemostats and Sealants market. In this Market Outlook article, Doug Devens, SmartTRAK's Senior Analyst, Biosurgery, does a deep dive, discussing what’s fueling this growth and reviews the top market trends you need to know for the year ahead.

  • Trend #1: Expanding Indications Fuel Increased Adoption of Fibrin Sealants
  • Trend #2: Increasing Use of Sealant Patch Products
  • Trend #3: New Plant-Based Technologies Gaining Ground
  • Trend #4: Biologic Sealants Ready for Bounce Back

DownloadMarket Outlook: Top Trends to Watch in Hemostats and Sealants

Read More

Topics: Biosurgery-Hemostats and Sealants

Q218 US Hemostats and Sealants Market Recap: Revenue Grows

Posted by Doug Devens on 8/29/18 12:04 PM

Baxter, Ethicon and Integra lead the way...

As reported in  SmartTRAK’s Financial Dashboard, the US market for Hemostats and Sealants grew +3.8% YoY in Q218, an increase from +3.1% growth rate overall in Q118. Fibrin sealants continue to lead the way with +7.2% YoY growth in Q218, and thrombin hemostats had a very good quarter with +7.2% growth YoY...

Among the many topics covered in the full Q218 Hemostats and Sealants Market Recap are:

  • Ethicon Continues to Lead Hemostats and Sealants
  • Thrombins Come Back In Hemostats
  • Fibrin Continues To Shine In Sealants
  • Q218 events in the US Hemostats and Sealants Market
Read More

Topics: Biosurgery-Hemostats and Sealants

SmartTRAK Publication Alert: Q118 Hemostats and Sealants Market Recap

Posted by Doug Devens on 6/13/18 9:00 AM

SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its Q118 Hemostats and Sealants Market Recap.

Read More

Topics: Biosurgery-Hemostats and Sealants

SmartTRAK's Final 2017 Hemostats & Sealants Market Financial Results

Posted by Doug Devens on 3/22/18 4:39 PM

The US market for Hemostats and Sealants recovered in Q417, up +5.0% YoY, in line with historic growth rates. While biologic sealants continue to lag, every other segment grew, led by absorbable hemostats and fibrin sealants.

SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its 2017 Hemostats & Sealants Market Recap and Financial Dashboard.

As reported in SmartTRAK’s Financial Dashboard, almost every manufacturer competing in the Hemostats and Sealants market saw revenue growth in Q417/FY17, led by BaxterEthicon and Cryolife in Q417 and by Baxter and Integra for FY17 ...

Read More

Topics: Biosurgery-Hemostats and Sealants

SmartTRAK Publication Alert: Q317 Hemostats and Sealants Quarterly Market Recap

Posted by Doug Devens on 12/18/17 7:11 PM

Q317 Market Recap Biosurgery Hemostats & Sealants: Supply Chain Disruptions 

By Doug Devens, Senior Analyst Biosurgery

Surprisingly, the US market for Hemostats and Sealants was down vs Q217 and YoY, an anomaly from historic growth rates, primarily due to supply chain disruptions and softness in the thrombin hemostat segment.

Read More

Topics: Biosurgery-Hemostats and Sealants

BioMedGPS Expands Coverage of Wound Care Market with Launch of US Hemostats & Sealants

Posted by Susan Paquette on 10/12/17 8:50 AM

BioMedGPS announces expanded coverage of SmartTRAK Business Intelligence for the Surgical Wound Market with the addition of its newest module, US Hemostats & Sealants.

 Interested in the future of Biosurgery? Download our Hemostats & Sealants Article now!

Read More

Topics: Biosurgery-Hemostats and Sealants

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts